NCT03426605View on ClinicalTrials.gov

A Study of LAM-003 in Patients With Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 16, 2018

Primary Completion Date

February 20, 2020

Study Completion Date

October 5, 2020

Conditions
OncologyAcute Myeloid Leukemia
Interventions
DRUG

Open Label LAM-003

LAM-003

Trial Locations (6)

10021

Weill Cornell Medical College, New York

21201

University of Maryland, Baltimore

22031

Virginia Cancer Specialists, Fairfax

06511

Yale University, New Haven

02215

Dana Farber Cancer Institute, Boston

07601

Hackensack Meridien Health, Hackensack

Sponsors
All Listed Sponsors
lead

OrphAI Therapeutics

INDUSTRY

NCT03426605 - A Study of LAM-003 in Patients With Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter